Balanced news tone
News Sentiment
GOSS sentiment intelligence
Gossamer Bio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
47
Balanced news tone
67 relevant articles
News tone and price action are not far from neutral.
74/100 classification confidence.
directly relevant articles
high-authority source matches
-2.0% over one week, +4.8% over four weeks, trend inactive, and below fair value.
Gossamer Bio (NASDAQ: GOSS) wins approval to boost authorized shares to 4.0B
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
74/100 classification
One-week reaction
-2.0%
Price reacting lower
Trend fit
Trend inactive
4.8% over four weeks
Fair value
-86.1%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
10
Neutral
40
Negative
17
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Stock Titan
Direct company coverage
Gossamer Bio (NASDAQ: GOSS) wins approval to boost authorized shares to 4.0B
Gossamer Bio (NASDAQ: GOSS) stockholders have approved a major increase in authorized common stock from 700 million to 4 billion shares. This decision, made at a special meeting on July 14, 2026, supports potential future share issuances related to new convertible notes, purchase
- Tone
- Negative 38/100
- Event
- Regulatory and legal
- Published
- 15 Jul 2026 10:12
- Source
- Stock Titan
Stocktwits
Direct company coverage
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 20:30
- Source
- Stocktwits
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
TradingView
Direct company coverage
Price to earnings forward of Gossamer Bio, Inc. – MUN:4GB
This article provides financial information for Gossamer Bio, Inc. (MUN:4GB), specifically focusing on its forward Price to Earnings (P/E) ratio. It indicates that the market was closed with no trades at the time of publication. The content appears to be a financial data page fro
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 13:09
- Source
- TradingView
Quartr
Direct company coverage
Gossamer Bio (GOSS) Proxy filing Summary
Gossamer Bio (GOSS) has released a proxy filing summary detailing its upcoming annual meeting scheduled for June 4, 2026. Shareholders will vote on the election of two Class II directors, the ratification of Ernst & Young LLP as the independent auditor, and an advisory vote on ex
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 07:10
- Source
- Quartr
Moomoo
Direct company coverage
Gossamer Bio (GOSS) Income Statement & Earnings
This article provides details on Gossamer Bio's income statement and earnings. As of the time of publication, specific financial figures and comprehensive analysis are not yet available, but the article focuses on key aspects of the company's financial performance.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 Jul 2026 15:40
- Source
- Moomoo
ACCESS Newswire
Direct company coverage
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Gossamer Bio, Inc. (GOSS) for potential corporate wrongdoing. The firm is encouraging shareholders who purchased Gossamer securities before June 16, 2025, and still hold them, to learn more about the investigat
- Tone
- Negative 20/100
- Event
- Regulatory and legal
- Published
- 09 Jul 2026 11:00
- Source
- ACCESS Newswire
Quartr
Direct company coverage
Gossamer Bio (GOSS) Q1 2025 earnings summary
Gossamer Bio (GOSS) reported its Q1 2025 earnings, highlighting the near completion of new patient screening for its pivotal phase III PROSERA study in PAH, with topline results expected in February 2026. The company ended Q1 2025 with $257.9 million in cash, providing a runway i
- Tone
- Positive 64/100
- Event
- Earnings
- Published
- 09 Jul 2026 04:10
- Source
- Quartr
Global Legal Chronicle
Direct company coverage
Gossamer Bio Announces Exchange Offer and Consent Solicitation for Convertible Senior Notes
Gossamer Bio, Inc., a biopharmaceutical company specializing in treatments for pulmonary hypertension, has successfully completed an exchange offer and consent solicitation for its convertible senior notes. The transaction was advised by DLA Piper, with Cantor Fitzgerald & Co. al
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 23:40
- Source
- Global Legal Chronicle
Finviz
Direct company coverage
GOSS - Gossamer Bio Inc Dividends
This article provides detailed financial data and performance metrics for Gossamer Bio Inc. (NASDAQ: GOSS), including its last close price, market capitalization, income, sales, and various analyst estimates. The company's stock experienced a 2.41% decrease and shows significant
- Tone
- Negative 39/100
- Event
- Analyst action
- Published
- 07 Jul 2026 15:13
- Source
- Finviz
AD HOC NEWS
Direct company coverage
Gossamer Bio focuses on respiratory pipeline as markets weigh biotech valuations
Gossamer Bio Inc. is a biopharmaceutical company that focuses on developing treatments for respiratory and immunological conditions. The company's strategy involves advancing drug candidates through clinical trials, with investors closely watching key data readouts and regulatory
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 07 Jul 2026 12:13
- Source
- AD HOC NEWS
ACCESS Newswire
Direct company coverage
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential corporate wrongdoing by Gossamer Bio, Inc. (NASDAQ:GOSS) and its officers/directors. Investors who purchased Gossamer securities before June 16, 2025, and still hold them, are encouraged to contact the firm to assist w
- Tone
- Negative 31/100
- Event
- Regulatory and legal
- Published
- 07 Jul 2026 11:00
- Source
- ACCESS Newswire
TradingView
Direct company coverage
Price to earnings forward of Gossamer Bio, Inc. – DUS:4GB
This article presents the price to earnings forward data for Gossamer Bio, Inc. (DUS:4GB). It highlights the current period value and change, based on data provided by various financial services. The piece is primarily a data presentation from TradingView.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 Jul 2026 02:00
- Source
- TradingView
ACCESS Newswire
Direct company coverage
Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gossamer Bio, Inc. (NASDAQ:GOSS) securities who bought prior to June 16, 2025, and still hold them. The investigation aims to determine if Gossamer's officers and/or directors engaged
- Tone
- Negative 19/100
- Event
- Regulatory and legal
- Published
- 05 Jul 2026 11:00
- Source
- ACCESS Newswire
Market source
Direct company coverage
Gossamer Bio (GOSS) Stock Fair Value Moves Lower After Mixed Analyst Target Changes
Gossamer Bio's fair value estimate has been reduced from $4.46 to $3.86 due to mixed analyst commentary, despite some firms maintaining a "Buy" rating. While H.C. Wainwright sees upside post-dilution and balance sheet cleanup, Goldman Sachs suspended its rating due to going conce
- Tone
- Negative 37/100
- Event
- Analyst action
- Published
- 02 Jul 2026 14:13
- Source
- Market source
Investing.com Canada
Direct company coverage
Form 13D/A Gossamer Bio For: 1 July By Investing.com
This article from Investing.com announces the filing of Form 13D/A for Gossamer Bio on July 1. It is a brief news item indicating a regulatory filing has occurred for the company GOSS, which saw a 1.82% increase.
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 02 Jul 2026 02:13
- Source
- Investing.com Canada
Stock Titan
Direct company coverage
D.E. Shaw discloses 8.3% Gossamer Bio (GOSS) ownership stake
D.E. Shaw-affiliated entities have reported an 8.3% beneficial ownership stake in Gossamer Bio, Inc. (GOSS) common stock, totaling 40,630,726 shares out of 488,846,722 outstanding as of June 5, 2026. This ownership is distributed among Valence (7.8%), Cogence (0.4%), and funds ma
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 02 Jul 2026 02:13
- Source
- Stock Titan
Investing.com
Direct company coverage
Gossamer Bio sets conversion rate for 2030 convertible notes
Gossamer Bio (NASDAQ:GOSS) has announced the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030, set at 5,347.5936 shares of common stock per $1,000 principal amount. The biopharmaceutical company also established an initial exercise price
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 01:13
- Source
- Investing.com
Business Wire
Direct company coverage
Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 13:00
- Source
- Business Wire
Stock Titan
Direct company coverage
Gossamer Bio fixes note conversion at $0.19, warrants at $0.34
Gossamer Bio (NASDAQ: GOSS) has set the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030 at 5,347.5936 shares per $1,000 principal amount, resulting in a conversion price of approximately $0.19 per share. Additionally, the initial exercis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 13:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Gossamer Bio (NASDAQ: GOSS) sets note conversion rate and warrant exercise price
Gossamer Bio (NASDAQ: GOSS) has announced the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030 and the exercise price for its Purchase Warrants. Each $1,000 principal amount of notes will convert into 5,347.5936 shares of common stock, im
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 13:08
- Source
- Stock Titan
TradingView
Direct company coverage
Price to sales forward of Gossamer Bio, Inc. – NASDAQ:GOSS
This article provides a financial data point for Gossamer Bio, Inc. (NASDAQ: GOSS), specifically its forward price-to-sales ratio. The content appears to be a stub or a section from a larger financial data platform, indicating the period, value, and change for this metric.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 00:39
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of Gossamer Bio, Inc. – NASDAQ:GOSS
The article focuses on the "Price to book forward" financial metric for Gossamer Bio, Inc. (NASDAQ: GOSS). It provides access to this specific financial data for the company, indicating that additional historical values, percentage changes, and comparison periods are available on
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 19:10
- Source
- TradingView
Investing.com Australia
Direct company coverage
H.C. Wainwright cuts Gossamer Bio stock price target to $2 on debt exchange By Investing.com
H.C. Wainwright has reduced its price target for Gossamer Bio Inc. (NASDAQ:GOSS) from $5 to $2, while maintaining a Buy rating, citing the company's recent convertible note exchange offer as the primary reason. Gossamer Bio's management anticipates submitting a New Drug Applicati
- Tone
- Negative 38/100
- Event
- Analyst action
- Published
- 27 Jun 2026 02:39
- Source
- Investing.com Australia
Investing.com
Direct company coverage
H.C. Wainwright cuts Gossamer Bio stock price target to $2 on debt exchange
H.C. Wainwright reduced its price target for Gossamer Bio Inc. (NASDAQ:GOSS) to $2 from $5, while maintaining a Buy rating, citing the company's recent convertible note exchange offer and consent solicitation as the primary reason. This debt restructuring aims to fully fund opera
- Tone
- Negative 35/100
- Event
- Analyst action
- Published
- 26 Jun 2026 23:40
- Source
- Investing.com
TradingView
Direct company coverage
Gossamer Bio, Inc. Actuals & Estimates (NASDAQ:GOSS)
This article provides current financial actuals and analyst estimates for Gossamer Bio, Inc. (NASDAQ:GOSS), including its stock price, market capitalization, volatility, and upcoming earnings dates. It highlights recent stock performance, revenue, net income, and offers a summary
- Tone
- Negative 30/100
- Event
- Earnings
- Published
- 25 Jun 2026 22:38
- Source
- TradingView
The National Law Review
Direct company coverage
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Gossamer Bio, Inc. (GOSS) for potential corporate wrongdoing. The firm is encouraging shareholders who purchased Gossamer securities before June 16, 2025, and still hold them, to contact them to assist with the
- Tone
- Negative 40/100
- Event
- Regulatory and legal
- Published
- 25 Jun 2026 15:10
- Source
- The National Law Review
Simply Wall Street
Direct company coverage
Gossamer Bio (NasdaqGS:GOSS) Stock Forecast & Analyst Predictions
Gossamer Bio (GOSS) is projected to grow earnings and revenue significantly, with analysts forecasting profitability by 2028. However, the company faces major risks including shareholder dilution, negative equity, high stock volatility, and Nasdaq's minimum bid price requirement.
- Tone
- Negative 15/100
- Event
- Earnings
- Published
- 25 Jun 2026 11:39
- Source
- Simply Wall Street
TradingKey
Direct company coverage
Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Gossamer Bio Inc (GOSS) has an earnings forecast score of 6.50, ranking 327 out of 388 in the Biotechnology & Medical Research industry, with an average analyst price target of $9.00. Analysts' consensus based on 8 ratings is "Hold" for GOSS stock, with an anticipated revenue of
- Tone
- Positive 57/100
- Event
- Earnings
- Published
- 23 Jun 2026 22:10
- Source
- TradingKey
ACCESS Newswire
Direct company coverage
Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Gossamer Bio, Inc. (GOSS) on behalf of investors who purchased securities prior to June 16, 2025, and continue to hold them. The investigation focuses on potential corporate wrongdoing by the company's o
- Tone
- Negative 29/100
- Event
- Regulatory and legal
- Published
- 23 Jun 2026 11:00
- Source
- ACCESS Newswire